All In Biotech

NDA 201688 · Viatris

Tobi Podhaler

Tobramycin · Inhalation · Aminoglycoside Antibacterial

Orphan

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 22, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

15,248

12,015 serious, 1,542 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

TOBI Podhaler is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ] . TOBI Podhaler is an aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >80%, or patients colonized with Burkholderia cepacia ( 1 )

Mechanism: Tobramycin is an aminoglycoside antibacterial [see Clinical Pharmacology (12.4) ] . Mechanism of Action Tobramycin is an aminoglycoside antibacterial produced by Streptomyces tenebrarius . It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against Gram-negative bacteria including P. aeruginosa . It is bactericidal in vitro at peak concentrations equal to or slightly greater than the minimum inhibitory concentration (MIC).

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TOBI PODHALER · TOBRAMYCIN 28MG · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea931
  • pneumonia927
  • off label use899
  • cough847
  • infective pulmonary exacerbation of cystic fibrosis842
  • cystic fibrosis778
  • condition aggravated743
  • drug ineffective742
  • death717
  • acute kidney injury691
  • hospitalisation691
  • infection511

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200480
200597
200676
2007124
200890
200999
2010101
2011208
2012213
2013288
2014659
20151,050
2016857
2017736
20181,177
20191,878
20201,727
20211,152
20221,047
2023883
20241,087
2025925
2026694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tobi Podhaler (Tobramycin)

2024 spending

$11.6M

Beneficiaries

332

1,054 claims

Per beneficiary

$35,051

$49.14 per unit

View as table
YearSpending
2020$0
2021$1,998,877
2022$10,243,673
2023$11,113,269
2024$11,636,780

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 791 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.